Best Options Strategy for BBIO
Looking for the best options strategy for BridgeBio Pharma, Inc. (BBIO)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live BBIO option chain right now, and a simple map from your view on BBIO to the strategy that fits it. Model any of them in the calculator before you trade.
About BridgeBio Pharma, Inc.
BridgeBio Pharma develops and commercializes medicines targeting genetic diseases, with a pipeline spanning small molecule drugs, gene therapies, and other modalities. The company's marketed product Attruby treats a form of heart amyloidosis by stabilizing the transthyretin protein, while Nulibry addresses molybdenum cofactor deficiency through synthetic enzyme replacement. Its clinical-stage candidates include infigratinib for growth disorders in children, encaleret for calcium regulation disorders, and several investigational therapies for muscular dystrophy and neurological conditions like Canavan disease. BridgeBio also pursues development programs across mendelian disorders and oncology.
The company generates revenue from product sales and leverages partnerships with major pharmaceutical and research organizations, including Novartis, Bayer, and Stanford University, to fund development efforts. As a biopharmaceutical firm founded in 2015 and based in Palo Alto, California, BridgeBio operates in the rare genetic disease space, where patient populations are small but treatment options limited and unmet medical needs substantial. The company's financial model depends on…
Today's top-scoring strategy for BBIO
Our engine ranks defined-risk strategies on the live BBIO chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Sell | 1× | CALL | $87.5 | $1.11 |
| Buy | 1× | CALL | $95 | $0.14 |
Simulazione
Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.
Analisi della strategia
Greche vs prezzo
Prezzo × volatilità (oggi)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $103 | −$622 | −$597 | −$570 | −$545 | −$521 |
| $99 | −$555 | −$521 | −$492 | −$467 | −$446 |
| $95 | −$420 | −$396 | −$377 | −$361 | −$349 |
| $90 | −$231 | −$235 | −$237 | −$238 | −$239 |
| $86 | −$52 | −$79 | −$100 | −$117 | −$130 |
| $82 | $53 | $28 | $4 | −$18 | −$36 |
| $78 | $90 | $78 | $64 | $47 | $31 |
| $74 | $96 | $94 | $89 | $80 | $70 |
| $70 | $97 | $97 | $96 | $93 | $88 |
| $66 | $97 | $97 | $97 | $96 | $95 |
| $62 | $97 | $97 | $97 | $97 | $97 |
Illustrative example at BBIO's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
BBIO is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on BBIO currently price in about 32% implied volatility, versus roughly 51% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$7,45 (±9%) in BBIO by 2026-08-21 — a range of roughly $74,75 to $89,66. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on BBIO trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Insider trading su BBIO (SEC Form 4)
Operazioni degli insider sul mercato aperto relative a BBIO negli ultimi sei mesi circa, tratte dalle comunicazioni SEC Form 4. Gli acquisti sul mercato aperto sono il segnale più raro e più forte — le vendite di routine effettuate nell'ambito di piani prestabiliti sono frequenti, quindi leggi un dato di vendita netta tenendolo presente.
| Insider | Azione | Azioni | Valore | Data |
|---|---|---|---|---|
| Ellis Andrea | Vendita | 17.167 | $1.4M | 2026-07-09 |
| Cook Jennifer E. | Vendita | 112.422 | $10.1M | 2026-07-09 |
| Cook Jennifer E. | Vendita | 36.167 | $3.0M | 2026-07-09 |
| Cook Jennifer E. | Vendita | 37.167 | $2.6M | 2026-06-24 |
| Cook Jennifer E. | Vendita | 2196 | $151K | 2026-06-23 |
| Valantine Hannah | Vendita | 2196 | $151K | 2026-06-23 |
Fonte: comunicazioni SEC Form 4 tramite Finnhub. Solo acquisti (P) e vendite (S) sul mercato aperto — assegnazioni, esercizi di opzioni, donazioni e ritenute fiscali sono esclusi. Contesto informativo, non consulenza sugli investimenti.
Earnings & IV crush
BBIO's next earnings report is due around 4 agosto 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
With earnings roughly 13 days out, BBIO's 32% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.
Key figures
- Market cap
- $16.2B
- Beta (vs market)
- 0.95
- 52-week range
- $42.09–$93.42 (78% up the range)
- Short interest
- 13.7% of float · 5.8 days to cover
With 13.7% of BBIO's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for BBIO
Start with your outlook on BBIO, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while BBIO stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open BBIO in the free calculator →
Domande frequenti
What is the best options strategy for BBIO?
It depends on your outlook. Bullish traders often use a long call or bull call spread on BBIO; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are BBIO options liquid enough to trade?
BridgeBio Pharma, Inc. (BBIO) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade BBIO options?
Buying a single BBIO call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade BBIO or any security. Do your own research.
Cosa fa BridgeBio Pharma, Inc.?
BridgeBio Pharma, Inc. (BBIO) opera nel settore Biotechnology. La sezione "Informazioni su BridgeBio Pharma, Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.
BridgeBio Pharma, Inc. paga dividendi?
Qui non mostriamo un rendimento da dividendo confermato per BridgeBio Pharma, Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.
Quando BridgeBio Pharma, Inc. pubblica gli utili?
I prossimi utili di BridgeBio Pharma, Inc. sono attesi intorno al 4 agosto 2026. La volatilità implicita di solito sale in avvicinamento alla pubblicazione e crolla bruscamente dopo (IV crush) — un aspetto importante per qualsiasi posizione in opzioni che mantieni oltre quella data.
Tickers related to BBIO
Comparing BBIO with similar names can help you choose the best options strategy:
Informazioni sull’azienda
- Sede
- 3160 Porter Drive, Suite 250, Palo Alto, CA, 94304, United States
- Settore
- Biotechnology
- Dipendenti
- 834
- CEO
- Dr. Neil Kumar Ph.D.
- Telefono
- 650 391 9740
- Sito web
- bridgebio.com
Best Options Strategy by Ticker →
Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.